Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

Table 2 Outcomes of RAS testing in Round 3 of the physician survey study

Outcome	No. of oncologists (%) (95% CI)
All oncologists	(N = 152)
Aware RAS testing should be performed prior to initiation of panitumumab	152 (100.0) (100.0–100.0)
Aware of the correct indication for panitumumab for treatment of patients with mCRC and wild-type RAS tumours^a	145 (95.4) (92.1–98.7)
Aware of patients’ tumour RAS status prior to initiation of panitumumab treatment in the past 6 months of routine clinical practice^b	143 (94.1) (90.3–97.8)
Administered panitumumab to only patients with mCRC and wild-type RAS in the past 6 months of routine clinical practice^c	131 (86.2) (80.7–91.7)
Subset of oncologists who administered panitumumab concurrently with oxaliplatin-containing chemotherapy	(N = 105)
Administered panitumumab with concurrent oxaliplatin-containing chemotherapy to only patients with mCRC and wild-type RAS in the past 6 months of routine clinical practice^d	97 (92.4) (87.3–97.5)

CI confidence interval, mCRC metastatic colorectal cancer
^aSix oncologists responded for treatment of patients with mutant RAS tumours and one oncologist gave a ‘not sure’ response
^bEight oncologists were unaware of patients’ tumour RAS status before initiation of panitumumab treatment and one oncologist gave a ‘not sure’ response
^cNineteen oncologists had administered panitumumab to patients with mCRC and mutant RAS tumours or with unknown tumour RAS status, and two oncologists gave a ‘not sure’ response
^dEight oncologists had administered panitumumab with concurrent oxaliplatin-containing chemotherapy to patients with mCRC and mutant RAS tumours or with tumour RAS status unknown

ISSN: 1471-2407